Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of this study is to compare the efficacy and safety of blinatumomab and donor lymphocyte infusion (DLI) versus blinatumomab alone in this setting. This is a multicenter retrospective study from centers of SFGM-TC. All transplanted patients who received blinatumomab salvage therapy were included. Patients who received DLI from 1 month before to 100 days after the starting of blinatumomab were included in the blina-DLI group. Seventy-two patients were included. Medium follow-up was 38 months. Fifty received blinatumomab alone and 22 the association blinatumomab-DLI. Two-year overall survival (OS) was 31% in the blinatumomab group and 43% in the blinatumomab-DLI group (p = 0.31). Studying DLI as a time dependent variable, PFS did not significantly differ between the 2 groups (HR:0.7, 95% CI: 0.4-1.5). In multivariate analysis, DLI was not a prognostic factor for OS, progression-free survival and progression/relapse incidence. Adverse events and graft-versus-disease rates were comparable in the 2 groups. In conclusion, adding DLI between 1 month before and 100 days after start of blinatumomab is safe and does not seem to improve outcomes in B-ALL patients who relapsed after allo-HCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-022-01846-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reduction of HLA antibodies by bi-specific antibody blinatumomab.
Hum Immunol
November 2024
HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States. Electronic address:
Donor specific antibodies against human leukocyte antigen (HLA) can cause engraftment failure in hemopoietic stem cell transplantation, or antibody mediated rejection in solid organ transplantation. To increase the chance of successful transplants, donor specific antibodies have to be reduced or depleted in patients with high levels of HLA antibodies. However, no current therapies have been proven to remove or reduce HLA antibodies effectively in the majority of patients.
View Article and Find Full Text PDFComplete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Hematol Rep
September 2024
Stem Cell Transplant Unit, "Agia Sofia Children's Hospital", 11527 Athens, Greece.
Article Synopsis
- Progress has been made in treating childhood acute lymphoblastic leukemia (ALL), but relapsed or refractory cases remain difficult to treat.
- A 23-month-old girl with high-risk B-ALL experienced early isolation relapse and, after failing multiple treatments including chemotherapy and novel therapies, was given the off-label monoclonal antibody inotuzumab ozogamicin (InO).
- The use of InO led to a significant reduction in her minimal residual disease, allowing her to achieve remission and successfully undergo an allogeneic stem cell transplant from a family donor.
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies.
Nat Biomed Eng
December 2024
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Bispecific antibodies (biAbs) used in cancer immunotherapies rely on functional autologous T cells, which are often damaged and depleted in patients with haematological malignancies and in other immunocompromised patients. The adoptive transfer of allogeneic T cells from healthy donors can enhance the efficacy of biAbs, but donor T cells binding to host-cell antigens cause an unwanted alloreactive response. Here we show that allogeneic T cells engineered with a T-cell receptor that does not convert antigen binding into cluster of differentiation 3 (CD3) signalling decouples antigen-mediated T-cell activation from T-cell cytotoxicity while preserving the surface expression of the T-cell-receptor-CD3 signalling complex as well as biAb-mediated CD3 signalling and T-cell activation.
View Article and Find Full Text PDFCAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.
Ann Hematol
November 2024
Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, 91054, Erlangen, Germany.
Chronic myeloid leukemia presenting de novo in the blast phase (CML-BP) is a rare diagnosis among pediatric malignancies. We report on a 16-year-old male who presented with CML-BP lymphoid at diagnosis. He was treated with shortened acute lymphoblastic leukemia induction plus the tyrosine kinase inhibitor (TKI) imatinib followed by dasatinib.
View Article and Find Full Text PDFA case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion.
Int J Hematol
November 2024
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Article Synopsis
- Acute lymphoblastic leukemia (ALL) has poor outcomes when it relapses after stem cell transplants, but blinatumomab, a new treatment, shows promise, especially for advanced B-cell ALL.
- The case study highlights a 56-year-old woman who achieved a third complete remission (CR) with two cycles of blinatumomab after developing isolated extramedullary relapse (EMR) post-transplant.
- The patient remained free of complications and experienced a confirmed 2-year treatment-free remission, suggesting that blinatumomab is an effective option for treating EMR of B-ALL after allo-HCT due to its association with lower tumor burdens.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!